BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37) - Wikidata - awgldk - TriplyDB

BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37)

BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37)

http://www.wikidata.org/entity/Q24677292

about

Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine The extracranial vascular theory of migraine--a great story confirmed by the facts.Possible site of action of CGRP antagonists in migraine.Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs Noncompetitive antagonism of BIBN4096BS on CGRP-induced responses in human subcutaneous arteries Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache.Vascular actions of calcitonin gene-related peptide and adrenomedullin.A role for the sensory neuropeptide calcitonin gene-related peptide in endothelial cell proliferation in vivo Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine CGRP receptor antagonism and migraine.The extracranial vascular theory of migraine: an artificial controversy.The role of the neurovascular scalp structures in migraine.Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.Intravital microscopy on a closed cranial window in mice: a model to study trigeminovascular mechanisms involved in migraine.The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men.Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries.BMS-927711 for the acute treatment of migraine.Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program.Differential localization and characterization of functional calcitonin gene-related peptide receptors in human subcutaneous arteries.Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers.The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers.

P2860

Q24632671-B7B2BC77-0435-45DC-88E4-86D7E8AB8023 Q34166916-5ED7B6AC-8685-4419-A20C-9BCAEB8CC908 Q34169056-ACD673DE-F08A-4DA8-A6E6-3B7A612185DD Q35045720-90800647-CDC2-403C-8525-474769FF2342 Q35048431-0600B992-E923-49FB-B42D-ACE6D0313179 Q35841612-7BF020BF-338E-4C41-A0B6-9E190F230421 Q35842993-095DD8D9-04AB-44FA-BE60-EB4D2358F4DC Q36159021-463A22E0-E515-482D-AEE7-3184F187E7D2 Q37276146-3449EB78-20D3-448F-8BE7-A14142B00707 Q37374122-0F1FA218-2EE0-4547-9C3C-36C18BBE5147 Q37826098-E93F85DA-9D1A-446E-9BEF-F1B0EDED1712 Q38020435-8A4D49A4-658F-47E0-948E-249422817287 Q39242677-AE64A469-317A-419B-8DEE-538F41E0BB96 Q40276569-4A314E25-E70D-470D-BE0B-CF21F306EAE6 Q42732396-405EDAA8-9B75-4B8B-BBFC-D36A3CCF88A7 Q42882636-7E6EBF30-4132-4EBE-8415-1FCA102844EF Q45137898-443B3331-3C9B-4E30-B355-D39CB0333F14 Q46698001-E8CDEA96-B91D-4F0D-8C35-56236632BFD8 Q46960593-3FAE074F-C32F-4958-8F59-B6E0549CC7BA Q47953579-4301355A-FE58-41F0-A239-767FB3340F55 Q49136131-E4DEAD47-4946-4069-9794-B6073A4E3D05

P2860

BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37)

http://www.wikidata.org/entity/Q24677292

description

2002 nî lūn-bûn

@nan

2002 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

BIBN4096BS is a potent competi ...... ry: comparison with CGRP(8-37)

@ast

BIBN4096BS is a potent competi ...... ry: comparison with CGRP(8-37)

@en

BIBN4096BS is a potent competi ...... ry: comparison with CGRP(8-37)

@nl

type

label

BIBN4096BS is a potent competi ...... ry: comparison with CGRP(8-37)

@ast

BIBN4096BS is a potent competi ...... ry: comparison with CGRP(8-37)

@en

BIBN4096BS is a potent competi ...... ry: comparison with CGRP(8-37)

@nl

prefLabel

BIBN4096BS is a potent competi ...... ry: comparison with CGRP(8-37)

@ast

BIBN4096BS is a potent competi ...... ry: comparison with CGRP(8-37)

@en

BIBN4096BS is a potent competi ...... ry: comparison with CGRP(8-37)

@nl

P1433

Q24677292-559C67FD-A4AD-4D3C-B36E-63C4E105739F

P1476

Q24677292-C4DDA1E5-A5F1-4467-8B68-D5BE0567D18A

P2093

Q24677292-4A133A15-6C22-4F40-88EE-382F284A48F6

Q24677292-614EC03E-02BE-4C18-B602-15C9036638D0

Q24677292-9E6D99F0-EC3F-4DA6-88CF-E18F1F246DB2

P2860

Q24677292-06F352E6-6CD3-4AA9-A1A8-E36BADB3AFE4

Q24677292-21A31E49-DE12-46A7-9573-B5542E1D2709

Q24677292-25C35B6B-0E14-470E-9753-5D6FD3EAF8FE

Q24677292-28EC6A6A-73D0-4B91-870C-71487056C310

Q24677292-2A02D6C5-0692-43B9-ACE7-4E969373BD17

Q24677292-305508FC-B1E4-4E59-AD80-04715DEF8DB9

Q24677292-447FF890-A5CC-4159-83B6-D92E240DB4E2

Q24677292-489755F7-8006-49B5-9608-D3BC5965BE97

Q24677292-516B1461-F6B1-44E4-BEFF-C893A6929907

Q24677292-601907E2-4737-40D3-8BBB-4C88BA5FC332

P304

Q24677292-49A7E46B-3F9D-4A93-B48E-F08B9B0D5837

P31

Q24677292-F82B8CCC-8798-4D51-9597-EE634C0FEEE6

P356

Q24677292-D437D6A3-3530-4249-901D-4DF6FE1F2CD9

P407

Q24677292-5E162E83-5AAC-4212-B6A2-171996E85649

P433

Q24677292-D96EA26D-9EC2-4222-8093-0A306886E358

P478

Q24677292-180D6A95-0D2F-452B-89DA-696DCB925FB8

P577

Q24677292-307E322A-8947-490E-B0E4-9CE9D5F37BE8

P5875

Q24677292-A655DF2C-8340-41C7-B827-493FC41F5E19

P698

Q24677292-8B00A45A-D2F3-49FE-B5A2-90E45C7390A0

P932

Q24677292-789377D7-BA36-4FFE-85A5-CE27E0E27FBA

P356

P1433

British Journal of Pharmacology

P1476

BIBN4096BS is a potent competi ...... ry: comparison with CGRP(8-37)

@en

P2093

Alberto J Kaumann

http://www.w3.org/2001/XMLSchema#string

Katja Bumann

http://www.w3.org/2001/XMLSchema#string

Raphaela Verheggen

http://www.w3.org/2001/XMLSchema#string

P2860

RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

Some quantitative uses of drug antagonists

CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors.

Protein kinases: tuners of the BKCa channel in smooth muscle.

Effects of sodium nitroprusside and other smooth muscle relaxants on cyclic GMP formation in smooth muscle and platelets.

Participation of 5-HT1-like and 5-HT2A receptors in the contraction of human temporal artery by 5-hydroxytryptamine and related drugs

Lack of a causal relationship between the vasodilator effect of papaverine and cyclic AMP production in the dog basilar artery.

Effect of papaverine on cyclic nucleotide levels in the isolated rat aorta.

P304

120-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0704682

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P577

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11393273

http://www.w3.org/2001/XMLSchema#string

P698

11976276

http://www.w3.org/2001/XMLSchema#string

P932

1762122

http://www.w3.org/2001/XMLSchema#string